Faculty profile

Mads Daugaard

ResearcherUrologic SciencesUniversity of British Columbia

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of British Columbia directory, so their courses may be missing. Find their university profile.

Mads Daugaard

Researcher

Urologic Sciences

Health Sciences

University of British Columbia

Vancouver, British Columbia, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
22 publications in the last five years, latest in 2026.
Senior (last) author on 7 recent papers, a sign of leading a research group.
Principal investigator on 5 research grants (5 CIHR), most recently in 2025.
Supervisor on 3 trainee awards (3 CIHR), most recently in 2023.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

398

Citations

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Prostate Cancer Glycosaminoglycans Chondroitin Sulfate Antibody-Drug Conjugates 3d Cell Models Artificial Intelligence Cell Counting Cell Cultures

Latest papers

Preclinical profiling of antibody drug conjugates targeting oncofetal chondroitin sulfate.
Cell death & disease · 2026
Recent advances in purpose-built 3D bioprinted cancer models for drug development.
Expert opinion on drug discovery · 2026 · senior author
Enhanced precision in cell culture analytics: leveraging artificial intelligence for unbiased and non-destructive assessment of cell growth and viability.
Cell death discovery · 2026

All 67 publications

Latest funding

Therapeutic antibodies targeting oncofetal glycosaminoglycans in prostate cancer
CIHR · 2025 · Nominated PI
$952,426
An integrated AI-powered platform for cell analytics
CIHR · 2024 · Nominated PI
$730,576
Characterization of a novel dual HDAC-PARP inhibitor for the treatment of Ewing Sarcoma in a 3-D printed human-mimetic bone model
CIHR · 2023 · Supervisor
$105,000

All 9 grants and awards

67 publications.

Preclinical profiling of antibody drug conjugates targeting oncofetal chondroitin sulfate.

Skafte A, Vidal-Calvo EE, Choudhary S, Mujollari J, Dagil R, Martin-Salazar A, Oo HZ, Duvnjak L, Theander TG, Daugaard M, Gustavsson T, Salanti A

Cell death & disease2026

DOI: 10.1038/s41419-026-08420-x PMID: 41580438

Recent advances in purpose-built 3D bioprinted cancer models for drug development.

Ramos L, Robinson M, Lallous N, Flannigan R, Daugaard M

Expert opinion on drug discovery2026Senior author

DOI: 10.1080/17460441.2026.2642320 PMID: 41913455

Enhanced precision in cell culture analytics: leveraging artificial intelligence for unbiased and non-destructive assessment of cell growth and viability.

Wong CP, Khazamipour N, Aalibagi S, Kapoor S, Ramos L, Saade JM, Dolleris C, Peterslund JML, Golnarian D, Farivar N, Daugaard M, Al Nakouzi N

Cell death discovery2026

DOI: 10.1038/s41420-026-03116-9 PMID: 41974652

Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker.

Pece A, Lovato G, Cela I, Mercatelli A, Ferro B, Nikkola J, Pagotto S, Grottola T, De Laurenzi V, Cicchetti R, Marchetti A, Schips L, Lattanzio R, Iacobelli S, Capone E, Black P, Daugaard M, Marchioni M, Sala G

Molecular oncology2026

DOI: 10.1002/1878-0261.70140 PMID: 41046347

Exploring B7-H4's Role in Prostate Cancer Dormancy after Androgen Deprivation Therapy: Extracellular Matrix Interactions and Therapeutic Opportunities.

Kang N, Xue H, Wong NKY, Lin YY, Classen A, Wu R, Oo HZ, Dong X, Trinh A, Lin D, Daugaard M, Ong C, Collins C, Gleave M, Wang Y

Molecular cancer research : MCR2025

DOI: 10.1158/1541-7786.mcr-24-0958 PMID: 39776163

Identifying Rare Germline Variants Associated with Metastatic Prostate Cancer Through an Extreme Phenotype Study.

Lin YY, Noghabi HS, Volik S, Bell R, Sar F, Haegert A, Chung HC, Fazli L, Oo HZ, Daugaard M, Kuo MH, Hsu SC, Imeda EL, Zanettini C, Queiroz L, Schlotmann B, Gheybi K, Cooper C, Kote-Jarai Z, Eeles R, Pan Prostate Cancer Group (PPCG), Kung HJ, Marchionni L, Weischenfeldt J, Miller KD, Rabinowitz A, Wang Y, Zhang HF, Sorensen PH, Carey MS, Gleave M, Hayes VM, Gibson WT, Collins CC

medRxiv : the preprint server for health sciences2025

DOI: 10.1101/2025.04.28.25326584 PMID: 40343042

Targeting IRE1α reprograms the tumor microenvironment and enhances anti-tumor immunity in prostate cancer.

Unal B, Kuzu OF, Jin Y, Osorio D, Kildal W, Pradhan M, Kung SHY, Oo HZ, Daugaard M, Vendelbo M, Patterson JB, Thomsen MK, Kuijjer ML, Saatcioglu F

Nature communications2024

DOI: 10.1038/s41467-024-53039-1 PMID: 39406723

Tumor-agnostic cancer therapy using antibodies targeting oncofetal chondroitin sulfate.

Vidal-Calvo EE, Martin-Salazar A, Choudhary S, Dagil R, Raghavan SSR, Duvnjak L, Nordmaj MA, Clausen TM, Skafte A, Oberkofler J, Wang K, Agerbæk MØ, Løppke C, Jørgensen AM, Ropac D, Mujollari J, Willis S, Garcias López A, Miller RL, Karlsson RTG, Goerdeler F, Chen YH, Colaço AR, Wang Y, Lavstsen T, Martowicz A, Nelepcu I, Marzban M, Oo HZ, Ørum-Madsen MS, Wang Y, Nielsen MA, Clausen H, Wierer M, Wolf D, Gögenur I, Theander TG, Al-Nakouzi N, Gustavsson T, Daugaard M, Salanti A

Nature communications2024

DOI: 10.1038/s41467-024-51781-0 PMID: 39215044

Pulsed Photothermal Therapy of Solid Tumors as a Precondition for Immunotherapy.

Farivar N, Khazamipour N, Roberts ME, Nelepcu I, Marzban M, Moeen A, Oo HZ, Nakouzi NA, Dolleris C, Black PC, Daugaard M

Small (Weinheim an der Bergstrasse, Germany)2024Senior author

DOI: 10.1002/smll.202309495 PMID: 38511548

The third symposium on treatment-induced neuroendocrine prostate cancer: insights and future directions.

Wang Y, Scurll J, Rascón IA, Cui C, Ni Y, Shi AM, Gangadharannambiar P, Wang Y, Akamatsu S, Beltran H, Cox M, Crea F, Daugaard M, Dong X, Haffner M, He H, Jachetti E, Kyprianou N, Li B, Ong CE, Rickman DS, Sen T, Zhu HH, Zoubeidi A, Gleave ME

Epigenomics2024

DOI: 10.1080/17501911.2024.2391729 PMID: 39225130

Something wrong or missing on this profile? Suggest a correction

Mads Daugaard

Research

Latest papers

Latest funding

Preclinical profiling of antibody drug conjugates targeting oncofetal chondroitin sulfate.

Recent advances in purpose-built 3D bioprinted cancer models for drug development.

Enhanced precision in cell culture analytics: leveraging artificial intelligence for unbiased and non-destructive assessment of cell growth and viability.

Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker.

Exploring B7-H4's Role in Prostate Cancer Dormancy after Androgen Deprivation Therapy: Extracellular Matrix Interactions and Therapeutic Opportunities.

Identifying Rare Germline Variants Associated with Metastatic Prostate Cancer Through an Extreme Phenotype Study.

Targeting IRE1&#x3b1; reprograms the tumor microenvironment and enhances anti-tumor immunity in prostate cancer.

Tumor-agnostic cancer therapy using antibodies targeting oncofetal chondroitin sulfate.

Pulsed Photothermal Therapy of Solid Tumors as a Precondition for Immunotherapy.

The third symposium on treatment-induced neuroendocrine prostate cancer: insights and future directions.

Frequent collaborators

Yuzhuo Wang

Jeffrey Bacha

Colin Collins

Amina Zoubeidi

Vijay Ramaswamy

Livia Garzia

Kednapa Thavorn

Natasha Kekre

Harold Atkins

Kednapa Thavorn

Brian Hutton

Martin Gleave

Cynthia Hawkins

Uri Tabori

Justin Presseau

Derek Jonker

Christopher Ong

Ryan Flannigan

Simon Wisnovsky

William Lockwood

Michael Cox

Giovanni Blandino

Alan So

Artem Cherkasov

Dean Fergusson

Yu Wang

James Ellis

Cathie Garnis

Peter Black

Xuesen Dong

Targeting IRE1α reprograms the tumor microenvironment and enhances anti-tumor immunity in prostate cancer.